RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
September 17, 2015 10:09 AM EDTCanaccord Genuity reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), and raised the price target to $44.00 (from $40.00), following announced Rocket 2 data. It's clear that the drug has clinically meaningful activity in glaucoma and in Canaccord's opinion is very approvable.
Analyst Corey Davis commented,... More
Aerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald
September 17, 2015 7:24 AM EDTCantor Fitzgerald analyst Caroline Corner reiterated a Buy rating and boosted her price target on Aerie Pharma (NASDAQ: AERI) to $40.00 (from $30.00) after the company announced positive results from the Rhopressa Phase III Rocket 2 trial.
Corner commented, "We are pleased to see this... More
Aerie Pharma (AERI) PT Raised to $48 at Brean Capital
September 17, 2015 6:59 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $48.00 (from $33.00), saying Rocket 2 is positive for Rhopressa.
Yang commented, "While approvals on Rhopressa and Roclatan are not expected until the 2017-2018 time... More
Aerie Pharma (AERI) PT Raised to $45 at Needham & Company
September 17, 2015 6:22 AM EDTNeedham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $45.00 (from $27.00) after the company reported top-line results from ROCKET-2, where Rhopressa met the primary endpoint by demonstrating non-inferiority in IOP-lowering vs. timolol.
Belanger... More
Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
September 16, 2015 4:04 PM EDTAerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa compared to timolol, the most widely used comparator. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.
Rhopressa Phase 3 Highlights for Rocket 2
Rhopressa, dosed both once-daily and twice-daily, achieved its primary... More